EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants

Robert L. Walsky, Shih-Hsun Cheng, Lin Chen, Min Ye, Jian Chen, Vance Warren, Alban J. Allentoff, Bo Wen, Kishore Katyayan, Usha Yerramilli, Satyendra Suryawanshi

Drug Metabolism and Disposition · 2026-11 · 100434

DOI: 10.1016/j.dmd.2026.100434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-11. Verfasst von Robert L. Walsky und 10 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An absorption, distribution, metabolism, and excretion study was performed to determine pharmacokinetic parameters, mass balance, and metabolite profiles of the androgen receptor ligand-directed degrader BMS-986365, a 1:1 mixture of R,R -BMS-986409 and R,S -BMS-986410 diastereomers, in humans. This open-label, single-center, nonrandomized study had a 2-part design. In part A, 8 healthy males received a microtracer intravenous infusion of [ 14 C]BMS-986365 following an oral dose of unlabeled BMS-986365 resulting in a systemic plasma clearance of 15.4 L/h, a steady-state volume of distribution of 445 L, and a mean half-life of 20.2 hours. In part B, 16 healthy male participants received a 1:1 oral dose of R,R -[ 14 C]BMS-986409 and R,S- BMS-986410 (n=8), or R,S- [ 14 C]BMS-986410 and R,R -BMS-986409 (n=8). Following oral dosing of the BMS-986365 diastereomers, time to maximum plasma concentration was ∼3.0 hours, determined fraction absorbed was 0.74, fraction surviving gut metabolism was 0.27, and oral bioavailability was 15.3%. In plasma, the main circulating drug species were a disproportionate metabolite M16 (BMT-617315, N- dealkylation followed by oxidation; mean across both arms: 66.2%), M15 (BMT-617088, N -dealkylation followed by reduction; 12.6%), and parent BMS-986365 (8.5%). Mass balance showed fecal excretion as the primary route of elimination (91.5% of dose) for BMS-986365, with renal excretion being low (2.0% of dose). Part B mean recovery of the administered radioactivity was 93.8%. In vitro phenotyping indicated oxidative formation of M6 ( N -dealkylation), M15, and M16 from BMS-986365 was CYP3A mediated, and that the formation of M4 (glutarimide ring hydrolysis and cyclization) was chirally selective and arylacetamide deacetylase mediated, with an 8.7-fold higher exposure from R,S- [ 14 C]BMS-986410 compared with R,R -[ 14 C]BMS-986409. SIGNIFICANCE STATEMENT This study provides an understanding of the absorption, distribution, metabolism, and excretion of the racemic androgen receptor ligand-directed degrader BMS-986365, a 1:1 mixture of R,R -BMS-986409 and R,S- BMS-986410 diastereomers, following oral and microtracer intravenous administration in healthy male participants. In vivo clinical and in vitro phenotyping data allowed mechanistic insights into the pharmacokinetic properties of BMS-986365 and will help guide future studies evaluating drug-drug interactions, special populations such as hepatic or renal impairment, and metabolite safety.

Förderung

  • Bristol-Myers Squibb Company

Zitieren

APA

Walsky, R. L., Cheng, S., Chen, L., Ye, M., Chen, J., Warren, V., Allentoff, A. J., Wen, B., Katyayan, K., Yerramilli, U., & Suryawanshi, S. (2026). Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants. Drug Metabolism and Disposition, 100434. https://doi.org/10.1016/j.dmd.2026.100434

Vancouver

Walsky RL, Cheng S, Chen L, Ye M, Chen J, Warren V, et al. Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants. Drug Metabolism and Disposition. 2026:100434. doi:10.1016/j.dmd.2026.100434

BibTeX
@article{Walsky2026,
  author = {Walsky, Robert L. and Cheng, Shih-Hsun and Chen, Lin and Ye, Min and Chen, Jian and Warren, Vance and Allentoff, Alban J. and Wen, Bo and Katyayan, Kishore and Yerramilli, Usha and Suryawanshi, Satyendra},
  title = {Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  pages = {100434},
  doi = {10.1016/j.dmd.2026.100434}
}
Kostenlos starten →